{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:02:36Z","timestamp":1780966956464,"version":"3.54.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bpobgyn.2024.102527","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T23:41:02Z","timestamp":1719618062000},"page":"102527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Reproductive decision-making in cancer susceptibility syndromes"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-2842","authenticated-orcid":false,"given":"Helena","family":"Carley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2024.102527_bib1","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/npjgenmed.2015.6","article-title":"Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet","volume":"1","author":"Ngeow","year":"2016","journal-title":"npj Genomic Med"},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib3","series-title":"Advances in the recognition and management of hereditary cancer","first-page":"123","author":"Kulkarni","year":"2016"},{"issue":"April","key":"10.1016\/j.bpobgyn.2024.102527_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.bpobgyn.2024.102527_bib6","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMra0802968","article-title":"Inherited susceptibility to common cancers","volume":"359","author":"Foulkes","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib7","series-title":"New clinical genetics","first-page":"301","author":"Read","year":"2015"},{"issue":"4","key":"10.1016\/j.bpobgyn.2024.102527_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: Statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1126\/science.2885916","article-title":"Structural Evidence for the Authenticity of the Human retinoblastoma gene","volume":"236","author":"Fung","year":"1986","journal-title":"Science (80)"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1631\/jzus.B073001","article-title":"Mechanisms of inherited cancer susceptibility","volume":"9","author":"Hodgson","year":"2008","journal-title":"J Zhejiang Univ - Sci B"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib12","series-title":"Prenatal diagnosis and pre-implantation genetic testing for germline cancer susceptibility gene variants [Internet]","year":"2023"},{"issue":"3","key":"10.1016\/j.bpobgyn.2024.102527_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"Canrisk tool\u2014a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.bpobgyn.2024.102527_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00438-020-01647-z","article-title":"GWAS in cancer: progress and challenges","volume":"295","author":"Liang","year":"2020","journal-title":"Mol Genet Genomics [Internet]"},{"issue":"5","key":"10.1016\/j.bpobgyn.2024.102527_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41431-021-01000-x","article-title":"The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice","volume":"30","author":"Forzano","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"23","key":"10.1016\/j.bpobgyn.2024.102527_bib16","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib17","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1210\/jc.2017-02529","article-title":"Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer","volume":"103","author":"Loveday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"39","key":"10.1016\/j.bpobgyn.2024.102527_bib18","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"10.1016\/j.bpobgyn.2024.102527_bib19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases","volume":"83","author":"Ponder","year":"2000","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.bpobgyn.2024.102527_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2024.102527_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2024.102527_bib23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.bpobgyn.2024.102527_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2014 association Analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bpobgyn.2024.102527_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib28","series-title":"Ovarian Cancer: Identifying and managing familial and genetic risk (NG241)","year":"2024"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib29","series-title":"Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer","year":"2023"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib30","first-page":"1","article-title":"Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database","volume":"58","author":"Dominguez-Valentin","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.bpobgyn.2024.102527_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CEG.S278054","article-title":"An update on immune checkpoint therapy for the treatment of lynch syndrome","volume":"14","author":"Therkildsen","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"issue":"10240","key":"10.1016\/j.bpobgyn.2024.102527_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib37","article-title":"APC-associated polyposis conditions","author":"Yen","year":"2022","journal-title":"GeneReviews"},{"issue":"3","key":"10.1016\/j.bpobgyn.2024.102527_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","article-title":"Guidelines for the management of hereditary colorectal cancer from the British society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom cancer genetics group (UKCGG)","volume":"69","author":"Monahan","year":"2020","journal-title":"Gut"},{"issue":"23","key":"10.1016\/j.bpobgyn.2024.102527_bib40","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation-carriers in the NCI LFS cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bpobgyn.2024.102527_bib41","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"10.1016\/j.bpobgyn.2024.102527_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jmg.2008.058958","article-title":"High frequency of de novo mutations in Li-Fraumeni syndrome","volume":"46","author":"Gonzalez","year":"2009","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jmedgenet-2020-106876","article-title":"UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants","volume":"58","author":"Hanson","year":"2021","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.bpobgyn.2024.102527_bib44","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","article-title":"Hereditary diffuse gastric cancer: updated clinical practice guidelines","volume":"21","author":"Blair","year":"2020","journal-title":"Lancet Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(22)00700-8","article-title":"Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study","volume":"24","author":"Lee","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2024.102527_bib47","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2019.1208","article-title":"Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers","volume":"5","author":"Roberts","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2024.102527_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ajmg.c.31743","article-title":"PTEN Hamartoma tumor syndrome in childhood: a review of the clinical literature","volume":"181","author":"Macken","year":"2019","journal-title":"Am J Med Genet Part C Semin Med Genet"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib49","first-page":"1","article-title":"PTEN hamartoma tumor syndrome","author":"Yehia","year":"2021","journal-title":"GeneReviews"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajhg.2010.11.013","article-title":"A clinical scoring system for selection of patients for pPTEN mutation testing is proposed on the basis of a prospective study of 3042 probands","volume":"88","author":"Tan","year":"2011","journal-title":"Am J Hum Genet [Internet]"},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bpobgyn.2024.102527_bib52","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41431-020-0651-7","article-title":"Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome","volume":"28","author":"Tischkowitz","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib53","author":"Mehta"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib54","author":"Veenhuis"},{"issue":"24","key":"10.1016\/j.bpobgyn.2024.102527_bib55","first-page":"1","article-title":"Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study","volume":"2045","author":"Ercan","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib56","article-title":"Ethical issues in prenatal genetic diagnosis guidance for clinical practice [Internet]","year":"2022","journal-title":"Report of the Joint Committee on Genomics in Medicine. London"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib57","unstructured":"Rakhra R, Taylor A, Cowley L. Genetic counselling framework for germline cancer susceptibility gene variant reproductive options [Internet]. [cited 2024 Apr 5]. Available from: https:\/\/www.ukcgg.org\/media\/12293\/genetic-counselling-framework-for-gcsgv-reproductive-options.pdf*."},{"issue":"13","key":"10.1016\/j.bpobgyn.2024.102527_bib58","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1158\/1078-0432.CCR-17-0652","article-title":"Retinoblastoma and Neuroblastoma predisposition and surveillance","volume":"23","author":"Kamihara","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib59","series-title":"Guidance for clinical practice","article-title":"Genetic testing in childhood","year":"2022"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10689-009-9271-7","article-title":"A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions","volume":"9","author":"Clancy","year":"2010","journal-title":"Fam Cancer"},{"issue":"5","key":"10.1016\/j.bpobgyn.2024.102527_bib62","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ejhg.2013.205","article-title":"Offering prenatal diagnostic tests: European guidelines for clinical practice","volume":"22","author":"Skirton","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib63","series-title":"Oxford Desk reference clinical genetics & Genomics","first-page":"706","author":"Firth","year":"2017"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib66","unstructured":"Guys & St Thomas NHS Foundation Trust. Pre-implantation genetic testing (PGT-M\/SR) [Internet]. [cited 2024 Apr 7]. Available from: https:\/\/www.guysandstthomas.nhs.uk\/our-services\/pre-implantation-genetic-testing-pgt-msr."},{"key":"10.1016\/j.bpobgyn.2024.102527_bib67","series-title":"Clinical Commissioning Policy: pre-implantation genetic diagnosis (PGD)","first-page":"1","year":"2013"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib68","unstructured":"Human Fertilisation & Embryo Authority. Using donated eggs, sperm or embryos in treatment [Internet]. [cited 2024 Apr 7]. Available from: https:\/\/www.hfea.gov.uk\/treatments\/explore-all-treatments\/using-donated-eggs-sperm-or-embryos-in-treatment\/."},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21926\/obm.genet.2002108","article-title":"Professionals' views on offering pre-Natal testing for adult onset cancer susceptibility. Reconciling personal and professional ethical Conflicts, Coping strategies and need for policy Transparency","volume":"4","author":"Cowley","year":"2020","journal-title":"OBM Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41431-021-00962-2","article-title":"What is a \u2018serious\u2019 genetic condition? The perceptions of people living with genetic conditions","volume":"30","author":"Boardman","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2024.102527_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jmg.37.2.157","article-title":"Clinical geneticists' attitudes and practice towards testing for breast cancer susceptibility genes","volume":"37","author":"Lucassen","year":"2000","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib72","first-page":"1","article-title":"Ethical preparedness in health research and care: the role of behavioural approaches","volume":"23","author":"Samuel","year":"2022","journal-title":"BMC Med Ethics [Internet]"},{"key":"10.1016\/j.bpobgyn.2024.102527_bib73","first-page":"1","article-title":"Beyond regulatory approaches to ethics: making space for ethical preparedness in healthcare research","author":"Lyle","year":"2022","journal-title":"J Med Ethics"},{"issue":"4","key":"10.1016\/j.bpobgyn.2024.102527_bib74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1258\/147775006779151184","article-title":"The UK Genethics Club: clinical ethics support for genetic services","volume":"1","author":"Lucassen","year":"2006","journal-title":"Clin Ethics"},{"issue":"July 2015","key":"10.1016\/j.bpobgyn.2024.102527_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rbms.2017.01.001","article-title":"Comparative preimplantation genetic diagnosis policy in Europe and the USA and its implications for reproductive tourism","volume":"3","author":"Bayefsky","year":"2016","journal-title":"Reprod Biomed Soc Online [Internet]"},{"issue":"6","key":"10.1016\/j.bpobgyn.2024.102527_bib76","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.fertnstert.2018.04.003","article-title":"Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions : an Ethics Committee opinion","volume":"109","year":"2018","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.bpobgyn.2024.102527_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.fertnstert.2023.03.003","article-title":"Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion","volume":"120","year":"2023","journal-title":"Fertil Steril"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693424000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693424000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T11:19:07Z","timestamp":1725794347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693424000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"alternative-id":["S1521693424000737"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2024.102527","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reproductive decision-making in cancer susceptibility syndromes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2024.102527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102527"}}